40 related articles for article (PubMed ID: 27520960)
21. A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM.
Deshaies F; Brunet A; Diallo DA; Denzin LK; Samaan A; Thibodeau J
Proc Natl Acad Sci U S A; 2005 May; 102(18):6443-8. PubMed ID: 15849268
[TBL] [Abstract][Full Text] [Related]
22. [The inhibitory effect of hyporesponsive peptide on human leukocyte antigen-DRbeta1 specific T cell activation].
Zhou Q; Cheng YJ; Li ZG; Zhou WH; Lu HS
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1505-9. PubMed ID: 14521731
[TBL] [Abstract][Full Text] [Related]
23. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.
Kropshofer H; Vogt AB; Thery C; Armandola EA; Li BC; Moldenhauer G; Amigorena S; Hämmerling GJ
EMBO J; 1998 Jun; 17(11):2971-81. PubMed ID: 9606180
[TBL] [Abstract][Full Text] [Related]
24. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
Xu M; Jackson R; Adams S; Humphreys RE
Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
[TBL] [Abstract][Full Text] [Related]
25. Peculiarities of the Presentation of the Encephalitogenic MBP Peptide by HLA-DR Complexes Providing Protection and Predisposition to Multiple Sclerosis.
Mamedov AE; Filimonova IN; Smirnov IV; Belogurov AA
Acta Naturae; 2021; 13(1):127-133. PubMed ID: 33959392
[TBL] [Abstract][Full Text] [Related]
26. Exhaustive Search of the Receptor Ligands by the CyCLOPS (Cytometry Cell-Labeling Operable Phage Screening) Technique.
Ishina IA; Filimonova IN; Zakharova MY; Ovchinnikova LA; Mamedov AE; Lomakin YA; Belogurov AA
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872428
[TBL] [Abstract][Full Text] [Related]
27. Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic Peptides.
Mamedov A; Vorobyeva N; Filimonova I; Zakharova M; Kiselev I; Bashinskaya V; Baulina N; Boyko A; Favorov A; Kulakova O; Ziganshin R; Smirnov I; Poroshina A; Shilovskiy I; Khaitov M; Sykulev Y; Favorova O; Vlassov V; Gabibov A; Belogurov A
Front Immunol; 2019; 10():3088. PubMed ID: 32010139
[TBL] [Abstract][Full Text] [Related]
28. Heterodimer HLA-DM Fused with Constant Fragment of the Heavy Chain of the Human Immunoglobulin Accelerates Influenza Hemagglutinin HA306-318 Loading to HLA-DR1.
Mamedov AE; Ponomarenko NA; Belogurov AA; Gabibov AG
Bull Exp Biol Med; 2016 May; 161(1):92-5. PubMed ID: 27265131
[TBL] [Abstract][Full Text] [Related]
29. Differential effect of polymorphism at HLA-DR1 beta-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides.
Newton-Nash DK; Eckels DD
J Immunol; 1993 Mar; 150(5):1813-21. PubMed ID: 7679697
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects on HLA-DR1-specific T-cell activation by influenza virus haemagglutinin-derived peptides.
Li X; Li R; Li Z
Tissue Antigens; 2006 Jan; 67(1):45-52. PubMed ID: 16451200
[TBL] [Abstract][Full Text] [Related]
31. Implication of HLA-DR residues at positions 67, 71, and 86 in interaction between HLA-DR11 and peptide HA306-320.
Zeliszewski D; Golvano JJ; Gaudebout P; Dorval I; Freidel C; Gebuhrer L; Betuel H; Borras-Cuesta F; Sterkers G
J Immunol; 1993 Dec; 151(11):6237-47. PubMed ID: 7504016
[TBL] [Abstract][Full Text] [Related]
32. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
33. Erratum to: Heterodimer HLA-DM Fused with Constant Fragment of the Heavy Chain of the Human Immunoglobulin Accelerates Influenza Hemagglutinin Peptide HA
Mamedov AE; Ponomarenko NA; Belogurov AA; Gabibov AG
Bull Exp Biol Med; 2016 Jul; 161(3):442-446. PubMed ID: 27520960
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
